Press Releases
July 25, 2013
Gilead Sciences Announces Second Quarter 2013 Financial Results
- Total Revenues of
- Product Sales of
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| (In thousands, except per share amounts) | 2013 | 2012 | 2013 | 2012 | |||||||||||
| Product sales | $ | 2,657,285 | $ | 2,321,240 | $ | 5,050,853 | $ | 4,529,582 | |||||||
| Royalty, contract and other revenues | 110,109 | 83,946 | 248,176 | 158,053 | |||||||||||
| Total revenues | $ | 2,767,394 | $ | 2,405,186 | $ | 5,299,029 | $ | 4,687,635 | |||||||
| Net income attributable to Gilead | $ | 772,605 | $ | 711,564 | $ | 1,494,791 | $ | 1,153,520 | |||||||
| Non-GAAP net income attributable to Gilead | $ | 839,725 | $ | 767,277 | $ | 1,641,668 | $ | 1,471,666 | |||||||
| Diluted EPS | $ | 0.46 | $ | 0.46 | $ | 0.89 | $ | 0.74 | |||||||
| Non-GAAP diluted EPS | $ | 0.50 | $ | 0.49 | $ | 0.98 | $ | 0.95 | |||||||
Product Sales
Product sales were driven primarily by growth in Gilead's antiviral
franchise during the second quarter of 2013. Contributing to the
increase were sales of Complera®/Eviplera®
(emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate
300 mg) and the launch of Stribild® (elvitegravir 150
mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate
300 mg) in the third quarter of 2012. Product sales for the second
quarter increased 20 percent in the U.S. and 4 percent in
Antiviral Product Sales
Antiviral product sales increased 15 percent to
| Three Months Ended | Six Months Ended | |||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||
| (In thousands, except percentages) | 2013 | 2012 | % Change | 2013 | 2012 | % Change | ||||||||||||||||
| Antiviral product sales | $ | 2,312,247 | $ | 2,012,283 | 15 | % | $ | 4,373,325 | $ | 3,938,089 | 11 | % | ||||||||||
| Atripla | 938,108 | 904,023 | 4 | % | 1,815,181 | 1,791,619 | 1 | % | ||||||||||||||
| Truvada | 807,779 | 785,933 | 3 | % | 1,508,021 | 1,544,196 | (2 | )% | ||||||||||||||
| Viread | 250,188 | 215,414 | 16 | % | 460,520 | 407,107 | 13 | % | ||||||||||||||
| Complera/Eviplera | 188,683 | 72,909 | 159 | % | 336,872 | 125,089 | 169 | % | ||||||||||||||
| Stribild | 99,394 | — | — | 191,542 | — | — | ||||||||||||||||
Cardiovascular Product Sales
Cardiovascular product sales increased 19 percent to
| Three Months Ended | Six Months Ended | |||||||||||||||||||||
| June 30, | June 30, | |||||||||||||||||||||
| (In thousands, except percentages) | 2013 | 2012 | % Change | 2013 | 2012 | % Change | ||||||||||||||||
| Cardiovascular product sales | $ | 234,854 | $ | 197,189 | 19 | % | $ | 449,247 | $ | 367,678 | 22 | % | ||||||||||
| Letairis | 128,257 | 101,634 | 26 | % | 246,364 | 188,922 | 30 | % | ||||||||||||||
| Ranexa | 106,597 | 95,555 | 12 | % | 202,883 | 178,756 | 13 | % | ||||||||||||||
Operating Expenses and Other
Non-GAAP research and development (R&D) expenses increased due to Gilead's continued investment in its product pipeline, particularly in liver disease and oncology. Non-GAAP selling, general and administrative (SG&A) expenses increased primarily due to the ongoing growth and expansion of Gilead's business.
Interest expense decreased primarily due to the repayment of the
convertible senior notes due in
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| (In thousands, except percentages) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
| Non-GAAP research and development expenses (1) | $ | 487,771 | $ | 371,398 | $ | 947,747 | $ | 702,736 | ||||||||
| Non-GAAP selling, general and administrative expenses (1) | $ | 376,336 | $ | 298,731 | $ | 709,400 | $ | 606,472 | ||||||||
| Interest expense | $ | (78,008 | ) | $ | (88,418 | ) | $ | (159,795 | ) | $ | (185,688 | ) | ||||
(1) Non-GAAP R&D expenses and SG&A expenses exclude the impact of acquisition-related, restructuring and stock-based compensation expenses where applicable.
Net Foreign Currency Exchange Impact
The net foreign currency exchange impact on second quarter 2013 product
sales and pre-tax earnings was unfavorable
Cash,
As of June 30, 2013, Gilead had
Product & Pipeline Updates Announced by
Antiviral Program
April:
-
Submission of a New Drug Application (NDA) to the
U.S. Food and Drug Administration (FDA ) for marketing approval to support the use of sofosbuvir and ribavirin (RBV) as an all-oral therapy for patients with genotype 2 and 3 chronic hepatitis C infection (HCV), and for sofosbuvir in combination with RBV and pegylated interferon (peg-IFN) for treatment-naïve patients with genotype 1, 4, 5 and 6 HCV infection. TheFDA granted priority review for this filing in June and set a target review date ofDecember 8, 2013 under the Prescription Drug User Fee Act. -
Detailed results from four Phase 3 studies (NEUTRINO, FISSION,
POSITRON and FUSION) evaluating sofosbuvir were presented at the
annual meeting of the
European Association for the Study of the Liver . The sofosbuvir NDA is supported primarily by data from these four Phase 3 studies. Sofosbuvir was administered to nearly 1,000 patients with HCV as part of an all-oral 12-week or 16-week treatment regimen in combination with RBV in genotypes 2 and 3, or with RBV and peg-IFN for 12 weeks in genotypes 1, 4, 5 and 6.
May:
- Interim results from the Phase 2 LONESTAR study, which evaluated eight and 12-week courses of therapy with the once-daily fixed-dose combination of sofosbuvir/ledipasvir with and without RBV in treatment-naïve, non-cirrhotic patients. In this study, 19/19 patients in the 12-week arm had a sustained virologic response four weeks after completing therapy (SVR4) and 40/41 patients in the eight-week arms had a sustained virologic response eight weeks after stopping therapy (SVR8), with one relapse occurring in the arm receiving sofosbuvir/ledipasvir without RBV. Two additional cohorts in the LONESTAR study evaluated a 12-week course of the fixed-dose combination of sofosbuvir/ledipasvir with or without RBV in patients who had previously failed therapy with an HCV-specific protease inhibitor-based regimen. Half of the treatment-experienced patients had documented, compensated cirrhosis. Ninety-five percent of patients in each arm achieved SVR4, one cirrhotic patient in the sofosbuvir/ledipasvir arm relapsed and one patient in the sofosbuvir/ledipasvir plus RBV arm was lost to follow-up.
- Plans to initiate a third Phase 3 study (ION-3) of sofosbuvir/ledipasvir for the treatment of HCV, evaluating the once-daily fixed-dose combination of sofosbuvir/ledipasvir for eight weeks with and without RBV and for 12 weeks without RBV in 600 non-cirrhotic, treatment-naïve genotype 1 HCV patients.
-
Submission of a Marketing Authorisation Application for sofosbuvir to
the
European Medicines Agency onApril 17, 2013 , which was fully validated and is under assessment. -
Granting of marketing authorization by the
European Commission for Stribild , a single tablet regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild. This approval allows for the marketing of Stribild in all 27 countries of theEuropean Union .
Oncology Program
May:
-
Results from a Phase 2 study (Study 101-08) evaluating idelalisib
(formerly GS-1101) in combination with rituximab for older patients
with treatment-naïve chronic lymphocytic leukemia. This regimen
achieved a complete response rate of 19 percent and an overall
response rate of 97 percent, with estimated progression-free survival
at 24 months of 93 percent. These results were presented at the
American Society of Clinical Oncology Annual Meeting.
June:
-
Interim results from a single-arm, open-label Phase 2 study (Study
101-09) evaluating idelalisib for the treatment of patients with
indolent non-Hodgkin's lymphoma that is refractory (non-responsive) to
rituximab and to alkylating-agent-containing chemotherapy.
Single-agent treatment with idelalisib achieved an overall response
rate of 53.6 percent, with a median duration of response at this
interim analysis of 11.9 months. Detailed study results were presented
at the
International Conference on Malignant Lymphoma .
Conference Call
At
A replay of the webcast will be archived on the company's website for
one year, and a phone replay will be available approximately two hours
following the call through
About Gilead
Non-GAAP Financial Information
Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (GAAP) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the table on pages 7 and 8.
Forward-looking Statements
Statements included in this press release that are not historical in
nature are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Gilead cautions readers that
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include: Gilead's ability to achieve its
anticipated full year 2013 financial results; Gilead's ability to
sustain growth in revenues for its antiviral, cardiovascular and
respiratory programs; availability of funding for state AIDS Drug
Assistance Programs (ADAPs); continued fluctuations in ADAP purchases
driven by federal and state grant cycles which may not mirror patient
demand and may cause fluctuations in Gilead's earnings; the possibility
of unfavorable results from clinical trials involving sofosbuvir, the
fixed-dose combination of sofosbuvir/ledipasvir and idelalisib; the
levels of inventory held by wholesalers and retailers which may cause
fluctuations in Gilead's earnings; Gilead's ability to submit NDAs for
new product candidates in the timelines currently anticipated, including
the fixed-dose combination of sofosbuvir/ledipasvir for the treatment of
HCV; Gilead's ability to receive regulatory approvals in a timely manner
or at all, for new and current products, including sofosbuvir for the
treatment of HCV; Gilead's ability to successfully commercialize its
products, including Stribild; Gilead's ability to successfully develop
its respiratory, cardiovascular and oncology/inflammation programs;
safety and efficacy data from clinical studies may not warrant further
development of Gilead's product candidates, including sofosbuvir, the
fixed-dose combination of sofosbuvir/ledipasvir and idelalisib; the
potential for additional austerity measures in European countries that
may increase the amount of discount required on Gilead's products;
fluctuations in the foreign exchange rate of the U.S. dollar that may
cause an unfavorable foreign currency exchange impact on Gilead's future
revenues and pre-tax earnings; and other risks identified from time to
time in Gilead's reports filed with the
Gilead owns or has rights to various trademarks, copyrights and trade
names used in our business, including the following: GILEAD®,
ATRIPLA® is a registered trademark belonging to Bristol-Myers
Squibb &
For more information on
|
GILEAD SCIENCES, INC. CONSOLIDATED STATEMENTS OF INCOME (unaudited) (in thousands, except per share amounts) |
||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales | $ | 2,657,285 | $ | 2,321,240 | $ | 5,050,853 | $ | 4,529,582 | ||||||||
| Royalty, contract and other revenues | 110,109 | 83,946 | 248,176 | 158,053 | ||||||||||||
| Total revenues | 2,767,394 | 2,405,186 | 5,299,029 | 4,687,635 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of goods sold | 684,663 | 617,345 | 1,319,111 | 1,198,276 | ||||||||||||
| Research and development | 523,902 | 396,244 | 1,021,534 | 854,455 | ||||||||||||
| Selling, general and administrative | 404,991 | 332,505 | 779,287 | 775,626 | ||||||||||||
| Total costs and expenses | 1,613,556 | 1,346,094 | 3,119,932 | 2,828,357 | ||||||||||||
| Income from operations | 1,153,838 | 1,059,092 | 2,179,097 | 1,859,278 | ||||||||||||
| Interest expense | (78,008 | ) | (88,418 | ) | (159,795 | ) | (185,688 | ) | ||||||||
| Other income (expense), net | (231 | ) | (1,075 | ) | (3,555 | ) | (35,160 | ) | ||||||||
| Income before provision for income taxes | 1,075,599 | 969,599 | 2,015,747 | 1,638,430 | ||||||||||||
| Provision for income taxes | 307,981 | 263,525 | 530,419 | 494,825 | ||||||||||||
| Net income | 767,618 | 706,074 | 1,485,328 | 1,143,605 | ||||||||||||
| Net loss attributable to noncontrolling interest | 4,987 | 5,490 | 9,463 | 9,915 | ||||||||||||
| Net income attributable to Gilead | $ | 772,605 | $ | 711,564 | $ | 1,494,791 | $ | 1,153,520 | ||||||||
| Net income per share attributable to Gilead common stockholders - basic | $ | 0.51 | $ | 0.47 | $ | 0.98 | $ | 0.76 | ||||||||
| Net income per share attributable to Gilead common stockholders - diluted | $ | 0.46 | $ | 0.46 | $ | 0.89 | $ | 0.74 | ||||||||
| Shares used in per share calculation - basic | 1,526,945 | 1,513,902 | 1,524,174 | 1,513,238 | ||||||||||||
| Shares used in per share calculation - diluted | 1,694,577 | 1,561,012 | 1,683,269 | 1,558,492 | ||||||||||||
|
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) (in thousands, except percentages and per share amounts) |
||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Cost of goods sold reconciliation: | ||||||||||||||||
| GAAP cost of goods sold | $ | 684,663 | $ | 617,345 | $ | 1,319,111 | $ | 1,198,276 | ||||||||
| Stock-based compensation expenses | (2,632 | ) | (2,119 | ) | (4,473 | ) | (4,220 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (21,264 | ) | (15,836 | ) | (42,528 | ) | (31,672 | ) | ||||||||
| Non-GAAP cost of goods sold | $ | 660,767 | $ | 599,390 | $ | 1,272,110 | $ | 1,162,384 | ||||||||
| Product gross margin reconciliation: | ||||||||||||||||
| GAAP product gross margin | 74.2 | % | 73.5 | % | 73.9 | % | 73.6 | % | ||||||||
| Stock-based compensation expenses | 0.1 | % | 0.1 | % | 0.1 | % | 0.1 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 0.8 | % | 0.7 | % | 0.8 | % | 0.7 | % | ||||||||
| Non-GAAP product gross margin(1) | 75.1 | % | 74.3 | % | 74.8 | % | 74.4 | % | ||||||||
| Research and development expenses reconciliation: | ||||||||||||||||
| GAAP research and development expenses | $ | 523,902 | $ | 396,244 | $ | 1,021,534 | $ | 854,455 | ||||||||
| Stock-based compensation expenses | (24,646 | ) | (20,355 | ) | (51,521 | ) | (138,978 | ) | ||||||||
| Restructuring expenses | (67 | ) | (1,576 | ) | (4,824 | ) | (7,090 | ) | ||||||||
| Acquisition related-transaction costs | — | (345 | ) | — | (345 | ) | ||||||||||
| Acquisition related-contingent consideration remeasurement | (11,418 | ) | (2,570 | ) | (17,442 | ) | (5,306 | ) | ||||||||
| Non-GAAP research and development expenses | $ | 487,771 | $ | 371,398 | $ | 947,747 | $ | 702,736 | ||||||||
| Selling, general and administrative expenses reconciliation: | ||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 404,991 | $ | 332,505 | $ | 779,287 | $ | 775,626 | ||||||||
| Stock-based compensation expenses | (28,675 | ) | (25,929 | ) | (61,726 | ) | (147,873 | ) | ||||||||
| Restructuring expenses | 306 | (7,251 | ) | (438 | ) | (10,407 | ) | |||||||||
| Acquisition related-transaction costs | (4 | ) | (594 | ) | (7,160 | ) | (10,874 | ) | ||||||||
| Acquisition related-amortization of purchased intangibles | (282 | ) | — | (563 | ) | — | ||||||||||
| Non-GAAP selling, general and administrative expenses | $ | 376,336 | $ | 298,731 | $ | 709,400 | $ | 606,472 | ||||||||
| Operating margin reconciliation: | ||||||||||||||||
| GAAP operating margin | 41.7 | % | 44.0 | % | 41.1 | % | 39.7 | % | ||||||||
| Stock-based compensation expenses | 2.0 | % | 2.0 | % | 2.2 | % | 6.2 | % | ||||||||
| Restructuring expenses | 0.0 | % | 0.4 | % | 0.1 | % | 0.4 | % | ||||||||
| Acquisition related-transaction costs | 0.0 | % | 0.0 | % | 0.1 | % | 0.2 | % | ||||||||
| Acquisition related-amortization of purchased intangibles | 0.8 | % | 0.7 | % | 0.8 | % | 0.7 | % | ||||||||
| Acquisition related-contingent consideration remeasurement | 0.4 | % | 0.1 | % | 0.3 | % | 0.1 | % | ||||||||
| Non-GAAP operating margin(1) | 44.9 | % | 47.2 | % | 44.7 | % | 47.3 | % | ||||||||
| Interest expense reconciliation: | ||||||||||||||||
| GAAP interest expense | $ | (78,008 | ) | $ | (88,418 | ) | $ | (159,795 | ) | $ | (185,688 | ) | ||||
| Acquisition related-transaction costs | — | — | — | 7,333 | ||||||||||||
| Non-GAAP interest expense | $ | (78,008 | ) | $ | (88,418 | ) | $ | (159,795 | ) | $ | (178,355 | ) | ||||
| Net income attributable to Gilead reconciliation: | ||||||||||||||||
| GAAP net income attributable to Gilead, net of tax | $ | 772,605 | $ | 711,564 | $ | 1,494,791 | $ | 1,153,520 | ||||||||
| Stock-based compensation expenses | 40,379 | 35,236 | 85,759 | 264,840 | ||||||||||||
| Restructuring expenses | (244 | ) | 6,426 | 5,124 | 12,772 | |||||||||||
| Acquisition related-transaction costs | 4 | 651 | 7,160 | 13,542 | ||||||||||||
| Acquisition related-amortization of purchased intangibles | 15,563 | 11,529 | 31,392 | 23,119 | ||||||||||||
| Acquisition related-contingent consideration remeasurement | 11,418 | 1,871 | 17,442 | 3,873 | ||||||||||||
| Non-GAAP net income attributable to Gilead, net of tax | $ | 839,725 | $ | 767,277 | $ | 1,641,668 | $ | 1,471,666 | ||||||||
|
|
Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Diluted earnings per share reconciliation: | ||||||||||||||||
| GAAP diluted earnings per share | $ | 0.46 | $ | 0.46 | $ | 0.89 | $ | 0.74 | ||||||||
| Stock-based compensation expenses | 0.02 | 0.02 | 0.05 | 0.17 | ||||||||||||
| Restructuring expenses | (0.00 | ) | 0.00 | 0.00 | 0.01 | |||||||||||
| Acquisition related-transaction costs | 0.00 | 0.00 | 0.00 | 0.01 | ||||||||||||
| Acquisition related-amortization of purchased intangibles | 0.01 | 0.01 | 0.02 | 0.01 | ||||||||||||
| Acquisition related-contingent consideration remeasurement | 0.01 | 0.00 | 0.01 | 0.00 | ||||||||||||
| Non-GAAP diluted earnings per share(1) | $ | 0.50 | $ | 0.49 | $ | 0.98 | $ | 0.95 | ||||||||
| Shares used in per share calculation (diluted) reconciliation: | ||||||||||||||||
| GAAP shares used in per share calculation (diluted) | 1,694,577 | 1,561,012 | 1,683,269 | 1,558,492 | ||||||||||||
| Share impact of current stock-based compensation rules | (1,228 | ) | (3,146 | ) | (1,453 | ) | (3,342 | ) | ||||||||
| Non-GAAP shares used in per share calculation (diluted) | 1,693,349 | 1,557,866 | 1,681,816 | 1,555,150 | ||||||||||||
| Non-GAAP adjustment summary: | ||||||||||||||||
| Cost of goods sold adjustments | $ | 23,896 | $ | 17,955 | $ | 47,001 | $ | 35,892 | ||||||||
| Research and development expenses adjustments | 36,131 | 24,846 | 73,787 | 151,719 | ||||||||||||
| Selling, general and administrative expenses adjustments | 28,655 | 33,774 | 69,887 | 169,154 | ||||||||||||
| Interest expense adjustments | — | — | — | 7,333 | ||||||||||||
| Total non-GAAP adjustments before tax | 88,682 | 76,575 | 190,675 | 364,098 | ||||||||||||
| Income tax effect | (21,562 | ) | (20,862 | ) | (43,798 | ) | (45,952 | ) | ||||||||
| Total non-GAAP adjustments after tax | $ | 67,120 | $ | 55,713 | $ | 146,877 | $ | 318,146 | ||||||||
| (1) Amounts may not sum due to rounding. | ||||||||||||||||
|
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) |
|||||||
|
June 30, |
December 31, | ||||||
| 2013 | 2012(1) | ||||||
| (unaudited) | |||||||
| Cash, cash equivalents and marketable securities | $ | 2,975,798 | $ | 2,582,086 | |||
| Accounts receivable, net | 1,895,913 | 1,751,388 | |||||
| Inventories | 1,935,147 | 1,744,982 | |||||
| Property, plant and equipment, net | 1,135,993 | 1,100,259 | |||||
| Intangible assets, net | 12,056,002 | 11,736,393 | |||||
| Goodwill | 1,188,157 | 1,060,919 | |||||
| Other assets | 1,437,364 | 1,263,811 | |||||
| Total assets | $ | 22,624,374 | $ | 21,239,838 | |||
| Current liabilities | $ | 4,937,138 | $ | 4,270,020 | |||
| Long-term liabilities | 6,343,852 | 7,418,949 | |||||
| Stockholders’ equity(2) | 11,343,384 | 9,550,869 | |||||
| Total liabilities and stockholders’ equity | $ | 22,624,374 | $ | 21,239,838 | |||
| (1) Derived from the audited consolidated financial statements as of December 31, 2012. |
|
(2) As of June 30, 2013, there were 1,528,890 shares of common stock issued and outstanding. |
|
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) (in thousands) |
|||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| 2013 | 2012 | 2013 | 2012 | ||||||||||||
| Antiviral products: | |||||||||||||||
| Atripla – U.S. | $ | 611,330 | $ | 570,835 | $ | 1,165,156 | $ | 1,132,879 | |||||||
| Atripla – Europe | 270,780 | 280,125 | 548,995 | 550,821 | |||||||||||
| Atripla – Other International | 55,998 | 53,063 | 101,030 | 107,919 | |||||||||||
| 938,108 | 904,023 | 1,815,181 | 1,791,619 | ||||||||||||
| Truvada – U.S. | 415,541 | 393,013 | 723,402 | 766,339 | |||||||||||
| Truvada – Europe | 324,992 | 328,814 | 657,019 | 650,690 | |||||||||||
| Truvada – Other International | 67,246 | 64,106 | 127,600 | 127,167 | |||||||||||
| 807,779 | 785,933 | 1,508,021 | 1,544,196 | ||||||||||||
| Viread – U.S. | 113,965 | 102,112 | 196,593 | 183,768 | |||||||||||
| Viread – Europe | 88,042 | 84,108 | 176,248 | 168,993 | |||||||||||
| Viread – Other International | 48,181 | 29,194 | 87,679 | 54,346 | |||||||||||
| 250,188 | 215,414 | 460,520 | 407,107 | ||||||||||||
| Complera / Eviplera – U.S. | 120,187 | 65,004 | 223,484 | 113,643 | |||||||||||
| Complera / Eviplera – Europe | 59,301 | 7,198 | 98,263 | 10,465 | |||||||||||
| Complera / Eviplera – Other International | 9,195 | 707 | 15,125 | 981 | |||||||||||
| 188,683 | 72,909 | 336,872 | 125,089 | ||||||||||||
| Stribild – U.S. | 96,961 | — | 188,939 | — | |||||||||||
| Stribild – Europe | 1,848 | — | 1,848 | — | |||||||||||
| Stribild – Other International | 585 | — | 755 | — | |||||||||||
| 99,394 | — | 191,542 | — | ||||||||||||
| Hepsera – U.S. | 9,871 | 8,172 | 22,821 | 20,981 | |||||||||||
| Hepsera – Europe | 9,268 | 15,420 | 20,491 | 29,385 | |||||||||||
| Hepsera – Other International | 2,317 | 2,599 | 4,567 | 5,122 | |||||||||||
| 21,456 | 26,191 | 47,879 | 55,488 | ||||||||||||
| Emtriva – U.S. | 4,768 | 4,770 | 9,297 | 8,863 | |||||||||||
| Emtriva – Europe | 1,584 | 1,741 | 3,335 | 3,552 | |||||||||||
| Emtriva – Other International | 287 | 1,302 | 678 | 2,175 | |||||||||||
| 6,639 | 7,813 | 13,310 | 14,590 | ||||||||||||
| Total Antiviral products – U.S. | 1,372,623 | 1,143,906 | 2,529,692 | 2,226,473 | |||||||||||
| Total Antiviral products – Europe | 755,815 | 717,406 | 1,506,199 | 1,413,906 | |||||||||||
| Total Antiviral products – Other International | 183,809 | 150,971 | 337,434 | 297,710 | |||||||||||
| 2,312,247 | 2,012,283 | 4,373,325 | 3,938,089 | ||||||||||||
| Letairis | 128,257 | 101,634 | 246,364 | 188,922 | |||||||||||
| Ranexa | 106,597 | 95,555 | 202,883 | 178,756 | |||||||||||
| AmBisome | 75,137 | 83,653 | 160,412 | 168,417 | |||||||||||
| Other products | 35,047 | 28,115 | 67,869 | 55,398 | |||||||||||
| 345,038 | 308,957 | 677,528 | 591,493 | ||||||||||||
| Total product sales | $ | 2,657,285 | $ | 2,321,240 | $ | 5,050,853 | $ | 4,529,582 | |||||||
Source:
Gilead Sciences, Inc.
Investors
Robin
Washington, 650-522-5688
Patrick O'Brien, 650-522-1936
Media
Amy
Flood, 650-522-5643